A Pilot Phase II Trial of Valspodar Modulation of Multidrug Resistance to Paclitaxel in the Treatment of Metastatic Carcinoma of the Breast (E1195): A Trial of the Eastern Cooperative Oncology Group

REFERENCES

• Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., et al. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 1989; 81: 116–124, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Goldstein L. J., Pastan I., Gottesman M. M. Multidrug resistance in human cancer. Crit Rev Oncol Hematol. 1992; 12: 243–253, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sikic B. Modulation of multidrug resistance: at the threshold. J Clin Oncol. 1993; 11: 1629–1635, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sikic B. I., Fisher G. A., Lum B. L., Halsey J., Beketic-Oreskovic L., Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997; 40(Suppl)S13–S19, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Jachez B., Nordmann R., Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. Journal of the National Cancer Institute. 1993; 85: 478–446, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991; 51: 4226–4233, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Twentymann P. R., Bleehen N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected][published erratum appears in European Journal Cancer 1992;28:616]. European Journal of Cancer. 1992; 27: 1639–1642, [CSA]
   Google Scholar
• Fracasso P. M., Fisher G. A., Wiehl J. G., Collins H., Hausdorff J., Williams K. M., Halsey J., Pearce T. E., Sikic B. I. Phase I trial of paclitaxel (Taxol) and SDZ PSC 833 in patients with solid tumors. Proc Am Soc Clin Oncol. 1995; 14, [CSA]
   Google Scholar
• Collins H. L., Fisher G. A., Hausdorff J., Lum B. L., Pearce T., Halsey J., Sikic B. I. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc Am Soc Clin Oncol 1995; 14, [CSA]
   Web of Science ®Google Scholar
• Schiller J. H., Storer B., Tutsch K., Arzoomanian R., Alberti D., Feierabend C., Spriggs D. Phase I. trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994; 12: 241–248, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Seidman A., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T., Lepore J., Gilewski T., Currie V., Crown J. Phase II. trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995; 13: 2575–2581, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sledge G. W., Jr, Neuberg D., Ingle J., Martino S., Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol. 1997; 16: 1a, [CSA]
   Google Scholar
• Holmes F. A., Valero V., Buzdar A. U., Booser D. J., Winn R., Tolcher A., et al. Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (mbc). The long & short of it. Proc Am Soc Clin Oncol. 1998; 17: 110a, [CSA]
   Google Scholar
• Smith R. E., Brown A. M., Mamounas E. P., Anderson S. J., Lembersky B. C., Atkins J. H., et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B- 26. J Clin Oncol. 1999; 17: 3403–3411, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Perez E. A., Vogel C. L., Irwin D. H., Kirshner J. J., Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001; 19: 4216–4223, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Reichman B. S., Seidman A. D., Crown J. P., Heelan R., Hakes T. B., Lebwohl D. E., Gilewski T. A., Surbone A., Currie V., Hudis C. A., et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993; 11: 1943–1951, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holmes F. A., Valero V., Walters R. S., Theriault R. L., Booser D. J., Giuseppe F., Buzdar A. U., Frye D., Gibbs H. R., Hoortobagyi G. N. The M.D. Anderson Cancer Center experience with taxol in metastatic breast cancer. Monogr Natl Cancer Inst. 1993; 15: 161–169, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Sledge G. W., Neuberg D., Bernardo P., Ingle J. N., Martino S., Rowinsky E. K., Wood W. C. Phase III. trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003; 21: 588–592, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cox D. R., Snell E. J. Analysis of Binary Data, Second Edition. London London; 26–105
   Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958; 53: 457–481, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• Sangrajrang S., Fellous A. Taxol resistance. Chemotherapy. 2000; 46: 327–334, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yusuf R. Z., Duan Z., Lamendola D. E., Penson R. T., Seiden M. V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003; 3: 1–19, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Trock B. J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997; 89: 917–931, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 2003; 10: 43–73, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fracasso P. M., Brady M. F., Moore D. H., Walker J. L., Rose P. G., Letvak L., Grogan T. M., McGuire W. P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001; 19: 2975–2982, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar